Skip to main content
. 2015 May 20;89(15):7813–7828. doi: 10.1128/JVI.00783-15

TABLE 2.

Antibody and inhibitor relative IC50s by the TZM-bl and A3R5 assaysa

Env variant and antibody or inhibitor TZM-bl assay
 A3R5 assay
Increased neutralization resistance of virus P value Relative IC50 (antibody, μg/ml; inhibitor, nM)
 Increased neutralization resistance of virus P value Relative IC50 (antibody, μg/ml; inhibitor, nM)
CA CF CA CF
Antibodies
    BAL
        huOKT4A CF 0.08 0.042 0.064
        hu5A8 — — — — — — — —
        4E10 — — — — CA 1 3.10 3.06
        10E8 CF 0.3 1.54 2.78 CF 0.6 1.23 1.62
        VRC01 CA 0.0001 0.22 0.071 CA 0.0001 0.22 0.055
        CH01 — — — — — — — —
        PGT126 CA 0.0001 0.8 0.053 CA 0.004 0.18 0.072
        PG9 — — — — — — — —
    WITO
        huOKT4A CF 0.8 0.074 0.074
        hu5A8 CA 0.0008 0.29 0.080 CA 0.0001 0.016 0.0011
        4E10 — — — — CA 1 3.74 2.69
        10E8 CA 1 3.44 3.09 CA 0.5 1.67 0.77
        VRC01 CA 0.0001 7.44 1.45 CA 0.0001 1.30 0.13
        CH01 — — — — CA 0.002 1.09 0.13
        PGT126 — — — — CA 0.3 3.16 2.03
        PG9 CA 0.0001 0.22 0.0070 CA 0.0001 0.071 0.0047
    CH040
        huOKT4A CF 0.8 0.082 0.10
        hu5A8 CF 1 0.21 0.21 CA 0.0001 0.024 0.0025
        4E10 — — — — — — — —
        10E8 CF 1 2.57 3.37 CF 0.6 0.82 1.86
        VRC01 CA 0.02 1.96 1.01 CA 0.0001 3.19 0.49
        CH01 — — — — — — — —
        PGT126 — — — — — — — —
        PG9 — — — — — — — —
    CH077
        huOKT4A CF 0.8 0.031 0.036
        hu5A8 CF 0.5 0.078 0.13 CA 0.009 0.012 0.0018
        4E10 — — — — CF 0.3 0.62 3.36
        10E8 CF 0.4 2.22 3.19 CA 0.2 2.29 0.82
        VRC01 CA 0.0001 3.34 1.26 CA 0.0001 2.23 0.27
        CH01 — — — — CA 0.4 1.88 0.33
        PGT126 CF 0.5 0.088 0.049 CA 0.0001 1.34 0.0049
        PG9 CA 0.0001 0.059 0.013 CA 0.0001 0.35 0.0034
Inhibitors
    BAL
        PMPA CF 0.002 772 2,001 CF 0.7 1,103 1,303
        Nevirapine CF 0.6 63.8 84.6 CF 1 53.25 54.8
        T-20 — — — — CA 1 93.0 85.4
        TAK-779 CF 0.7 517 807 CA 0.7 89.1 60.3
        Maraviroc CA 0.2 15.1 6.58 CF 0.4 1.03 4.17
    WITO
        PMPA CF 0.6 1,181 2,021 CF 0.7 436 547.5
        Nevirapine CF 0.7 40.3 58.4 CA 0.4 43.5 23.5
        T-20 — — — — CF 1 59.8 82.2
        TAK-779 CF 0.9 134 194 CA 0.2 74.4 33.2
        Maraviroc CA 0.3 19.4 11.4 CA 0.0001 20.5 2.56
    CH040
        PMPA CF 0.08 505 1,288 CA 0.6 1,327 856
        Nevirapine CA 0.6 86.3 44.6 CA 0.9 39.2 36.8
        T-20 CA 0.4 92.5 52.0 CA 1 91.4 72.8
        TAK-779 CA 0.05 77.9 43.3 CA 0.04 44.8 16.6
        Maraviroc CA 0.009 4.44 1.12 CA 0.0008 5.49 0.27
    CH077
        PMPA CF 0.5 1,080 1,661 CF 0.1 284.5 716
        Nevirapine CF 0.7 41.6 50.9 CA 0.9 33.6 27.1
        T-20 CF 1 58.9 68.0 CF 0.4 12.2 38.3
        TAK-779 CF 0.0005 9.77 43.1 CF 0.6 502 690
        Maraviroc CF 0.0001 0.088 1.60 CF 0.5 883 1,481
a

Antibody and inhibitor relative IC50s against cell-associated (CA) and cell-free (CF) virus are shown for TZM-bl and A3R5 target cells. Values were determined based on the neutralization dose responses from Fig. S2 and S3 in the supplemental material. Significant differences (in bold) between the log IC50s for the cell-associated and cell-free Env variants were assessed with ANOVA following a nonlinear regression analysis with a variable slope equation in GraphPad Prism. Only P values that were significant after Holm's adjustment for multiple comparisons were considered significant. Blank entries represent cases in which an antibody was not used in the A3R5 assay. —, cases in which the IC50 could not be calculated with the four-parameter logistic model.